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Abstract 
Conversion of normal cells to cancer is accompanied with changes in their metabolism. During this conversion, cell 
metabolism undergoes a shift from oxidative phosphorylation to aerobic glycolysis, also known as Warburg effect, 
which is a hallmark for cancer cell metabolism. In cancer cells, glycolysis functions in parallel with the TCA cycle and 
other metabolic pathways to enhance biosynthetic processes and thus support proliferation and growth. Similar 
metabolic features are observed in T cells during activation but, in contrast to cancer, metabolic transitions in T cells 
are part of a physiological process. Currently, there is intense interest in understanding the cause and effect relation-
ship between metabolic reprogramming and T cell differentiation. After the recent success of cancer immunotherapy, 
the crosstalk between immune system and cancer has come to the forefront of clinical and basic research. One of the 
key goals is to delineate how metabolic alterations of cancer influence metabolism-regulated function and differenti-
ation of tumor resident T cells and how such effects might be altered by immunotherapy. Here, we review the unique 
metabolic features of cancer, the implications of cancer metabolism on T cell metabolic reprogramming during anti-
gen encounters, and the translational prospective of harnessing metabolism in cancer and T cells for cancer therapy.
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Cancer cell metabolism and implications on T cell 
function in the tumor microenvironment
Since the early days of cancer biology research, it was 
determined that cancer cells acquire novel metabolic 
properties [1]. In a seminal discovery in 1923, Otto 
Warburg identified that cancer cells are characterized 
by an irreversible transition of their energy-producing 
machinery from mitochondrial respiration, where oxida-
tive phosphorylation (OXPHOS) occurs, to glycolysis, a 
biochemical process that occurs in the cytoplasm with-
out oxygen requirement, which can occur under aerobic 
and hypoxic conditions. Glycolysis results in the produc-
tion of ATP and lactate and is the preferred metabolic 
program of cancer cells even in presence of sufficient 
amounts of oxygen that could support OXPHOS. How-
ever, it was later appreciated that tumor cells also utilize 
OXPHOS [2–5] and that depletion of mitochondrial 
function mainly compromises the stemness features of 
cancer [6]. The very small percentage of this OXPHOS-
dependent fraction of cancer cells within the predomi-
nantly glycolytic cell population in tumors was the reason 
for which the role of OXPHOS in cancer remained unno-
ticed and neglected.
In addition to being the predominant metabolic pro-
gram of growing cancer cells, aerobic glycolysis is also 
operative during physiological states in the life of T cells. 
Naïve T cells utilize OXPHOS for energy generation, but 
upon activation via the T cell receptor (TCR), switch 
their metabolic program to glycolysis. Although energeti-
cally less efficient due to the production of lower number 
of ATP molecules per molecule of glucose compared to 
OXPHOS, glycolysis is required to support T cell effec-
tor differentiation and function [7, 8]. Various experi-
mental findings support the hypothesis that glycolysis 
has a selective advantage over oxidative phosphorylation 
during T cell activation. Glycolysis has higher ATP gen-
eration rate, can function under hypoxic and/or acidic 
conditions, and provides higher biosynthetic benefit and 
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better maintenance of redox balance than OXPHOS [9]. 
These properties of glycolysis are also beneficial for can-
cer cells [10]. However, an important difference between 
glycolysis in activated T cells and cancer cells is that, in 
cancer cells, this metabolic program is a consequence of 
cellular dysregulation due to oncogenic mutations, while 
in T cells glycolysis represents a physiologically regu-
lated metabolic adaptation [9, 11]. During exposure to 
activating external queues such as antigen, costimulatory 
signals, and cytokines, T cells also upregulate inhibitory 
receptors, which oppose the effects of activation signals 
and provide regulation of immune homeostasis and pre-
vention of autoimmunity. Importantly, tumors evade the 
immune system by expressing specific ligands for these 
inhibitory receptors, prototyped by PD-1, thus causing 
and maintaining T cell immunosuppression [12, 13]. Via 
T cell intrinsic mechanisms, these inhibitory receptors 
directly oppose the physiologic metabolic reprogram-
ming that occurs during T cell activation [14, 15].
A key mechanism by which cancer alters the functional 
fate of T cells is related to altered nutrient availability and 
metabolic state in the tumor microenvironment. Specifi-
cally, cancer cells develop glucose addiction and depend 
on glycolysis as their main metabolic program and thus 
acquire a high rate of glucose intake. As a consequence, 
T cells in the tumor microenrvironment undergo glucose 
deprivation due to high competition for glucose intake by 
cancer and activated T cells [16, 17]. In T lymphocytes, 
glucose uptake and catabolism is not simply a metabolic 
process for nutrient utilization and energy generation. 
Glycolysis has a key role on the T cell fate upon antigen-
encounter and is mandatory for the differentiation of the 
naïve T cells into antigen-specific T effectors (TEFF) [7, 
18, 19]. Thus, by creating a microenvironmental condi-
tion of glucose starvation for T cells, cancer inhibits the 
differentiation and expansion of tumor-specific T cells 
exposed to tumor associated antigens (TAA) that ren-
ders them unable to develop into tumor-specific TEFF 
cells [17]. Instead, these metabolic conditions, promote 
differentiation of T cells into Treg [18]. In addition to 
glucose, an equally important metabolite required for T 
cell differentiation and function is glutamine. Sufficient 
supply of glutamine and its utilization by T cells has an 
indispensable role for the development of TEFF cell fitness 
[20, 21]. Several cancers develop enhanced glutamine 
metabolism as a consequence of cell intrinsic carcino-
genic events including mutations and altered signaling 
pathways thereby becoming glutamine addicted [22]. As 
a consequence tumor-specific T cells residing in the can-
cer microenvironment are subjected to glutamine depri-
vation in addition to glucose competition.
Cancer cells not only compete for availability of 
key nutrients required for T cell activation, TEFF 
differentiation and adaptation of anti-tumor fitness, but 
also produce metabolic products, which are harmful for 
T cells [23]. To this end, it is important to understand the 
unique metabolic features of cancer and their implica-
tions in the tumor microenvironment and subsequently 
to resident T cells. Mechanistic understanding of these 
metabolic balances will provide the means to develop 
novel strategies for therapeutic targeting in order to har-
ness the maximum anti-tumor potential of the adaptive 
immune system. A stepwise description of these cancer-
specific metabolic modulations is outlined in the follow-
ing sections.
Metabolic features of cancer cells: glycolysis 
and Warburg effect, metabolic flexibility, metabolic 
flux
Adaptation to glycolysis and the Warburg effect
During oncogenesis, cancer cells acquire several features, 
which discriminate them from their nonmalignant coun-
terparts. One of these features is a change in the cellular 
metabolic program [10]. Cancer cells undergo metabolic 
adaptation and thereby gain selective survival and growth 
advantage (Fig.  1). Under physiological conditions most 
nonmalignant cells rely on OXPHOS as a primary meta-
bolic pathway to generate energy in the form of adeno-
sine triphosphate (ATP). Cancer cells, however, switch to 
glycolysis as primary energy source even in the presence 
of sufficient amounts of oxygen to support OXPHOS, a 
phenomenon known as the “Warburg effect” [24]. Nev-
ertheless, it should be pointed out that cancer cells have a 
significant degree of metabolic flexibility and rely on fatty 
acid β-oxidation (FAO) and OXPHOS for their needs, 
but these metabolic pathways are not primary sources 
of ATP. OXPHOS utilizes glucose-derived pyruvate pro-
duced through glycolysis, and oxygen in the mitochon-
dria to generate ATP, CO2, and H2O. Aerobic glycolysis, 
in contrast, generates ATP and lactate in the cytosol from 
glucose-derived pyruvate. Although aerobic glycolysis 
per se is less efficient in terms of ATP generation (glyco-
lysis produces 2 mol of ATP per mole of glucose, whereas 
mitochondrial respiration generates 36  mol of ATP per 
mole of glucose [25]), cancer cells circumvent this draw-
back by increasing the rate of glycolysis. Moreover, they 
benefit from other aspects of metabolism induced by 
aerobic glycolysis, such as elevated amounts of biosyn-
thetic precursors and increased reducing potential, in 
the form of NADH that is generated from the glycolytic 
pathway and in the form of NADPH that is generated 
from the pentose phosphate pathway (PPP), to which gly-
colytic mediators are shunted. Thus, the Warburg effect 
influences not only anabolic pathways leading to selec-
tive growth advantage of cancer cells but also supports 
redox balance and generation of biosynthetic precursors. 
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Because glycolysis can operate either in the presence 
or in the absence of oxygen, adaptation of the Warburg 
effect ensures that cancer cells can use the same meta-
bolic program, i.e. glycolytic, under aerobic as well as 
anaerobic/hypoxic conditions, which confers metabolic 
stability of cancer cells.
The molecular drivers causing the switch of cancer 
cell metabolism to aerobic glycolysis are diverse and are 
likely to act synergistically. Extensive studies have pro-
vided evidence that a series of sequential and independ-
ent mutations are required to develop the full potential 
of the Warburg effect [10, 24, 26]. Certain signaling path-
ways involved by such mutations or gene amplifications, 
outlined below, have key roles in regulating mechanisms 
that lead to the adaptation of the Warburg effect as the 
metabolic hallmark of cancer cells.
PI3K‑Akt‑mTOR‑FOXO
The phosphoinositide 3-kinase (PI3K) pathway is one of 
the most frequently altered signaling pathways in human 
cancers. Under physiological conditions the PI3Ks are a 
family of proteins involved in the regulation of cell sur-
vival, growth, metabolism, and glucose homeostasis [27]. 
This pathway is activated by mutations in tumor sup-
pressor genes, such as phosphatase and tensin homolog 
(PTEN), mutations in the components of the PI3K 
Fig. 1 Molecular alterations cause metabolic switching in cancer cells and severe metabolic changes in the tumor microenvironment. a Non malig-
nant (quiescent) cells rely on OXPHOS as primary ATP source under normoxic conditions. FAO also contributes to the cellular ATP pool. Without 
extrinsic stimuli the PI3K-Akt1 pathway is inactive. Downstream targets are also blocked, e.g. HK, PFK2, FOXO, HIF1α, mTOR, and NRF2. In addition, 
AMPK keeps HIF1α and mTOR in check. p53 participates in the repression of glycolysis by expression of TIGAR, PTEN, and SCO2. Myc as well as 
PGC1α are not active in quiescent cells and do not contribute to glycolysis. In order to sustain cellular homeostasis cells have a low energy demand 
and low biosynthetic activity. b Cancer cells acquire a series of mutations that foster glycolysis in several ways. Oncogenic PI3K-Akt1 signaling and 
inhibited AMPK signaling promote activation of pro-glycolytic events. These include activation of glycolytic enzymes namely HK and PFK2 and 
activation of transcription factors such as FOXO and in combination with hypoxia- HIF1α, which in turn induce the expression of glucose trans-
porters glut1 and glut4 and other glycolytic enzymes. Moreover, mTOR signaling is elevated which causes an increase in biosynthetic precursors. 
PI3K-Akt1-activated NRF2 induces expression of glycolytic genes as well as NADPH and anti-oxidants. PGC1α can also contribute to the cellular anti-
oxidant pool. Mutation or deletion of p53 causes loss of glycolytic inhibitors like TIGAR, PTEN, and SCO2. Oncogenic Myc induces the expression of 
glycolytic genes, glucose and glutamine transporters. Additionally, Myc enhances the amount of biosynthetic precursors by expression of GLS and 
the amount of cellular NAPDH and anti-oxidants via PKM2. Expression of IDO mediates the degradation of tryptophan to N-formylkynurenin, the 
first step of tryptophan catabolism in the kynurenin pathway. These mutations elevate nucleotide, amino acid, and lipid biosynthesis paired with 
enhanced catabolic pathways to enable cancer cells to proliferate rapidly
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complex, or by elevated signaling from receptor tyros-
ine kinases [28]. Upon activation, the PI3K pathway 
not only provides strong growth and survival signals to 
tumor cells but also has strong effects on their metabo-
lism. The best-studied effector downstream of PI3K is 
the RAC-alpha serine/threonine-protein kinase (AKT1). 
AKT1 is a critical driver of the tumor glycolytic pheno-
type and stimulates ATP generation through multiple 
mechanisms, ensuring that cells have the bioenergetic 
capacity required to respond to growth signals [29, 30]. 
AKT1 stimulates the expression of glucose transporters, 
phosphorylates key glycolytic enzymes, and alters their 
catalytic activity, e.g. hexokinase (HK) and phosphof-
ructokinase 2 [29, 31]. In addition, the activation and 
the prolonged signaling via AKT1 inhibits forkhead box 
subfamily O (FOXO) transcription factors by mediat-
ing their phosphorylation and sequestration in the cyto-
plasm, resulting in transcriptional changes that increase 
glycolytic capacity [32]. AKT1 also directly influences the 
mammalian target of rapamycin (mTOR) signaling path-
way. mTOR functions as a key metabolic hub, coupling 
growth signals to nutrient availability. Under physiologi-
cal stimulation triggered by amino acids, growth factors, 
stress, energy, as well as oxygen, mTOR stimulates pro-
tein and lipid biosynthesis and cell growth when suffi-
cient nutrient and energy are available [33–35]. mTOR is 
often constitutively activated during tumorigenesis [36]. 
AKT1 strongly activates mTOR-signaling pathway by 
inducing an inhibitory phosphorylation of tuberous scle-
rosis 2 (TSC2), a negative regulator of mTOR [27, 31].
AMPK‑mTOR
AMP-activated protein kinase (AMPK) is a crucial sen-
sor of energy status and has an important role in cellular 
responses to metabolic stress. Like the mTOR pathway, 
the AMPK pathway couples energy status to growth sig-
nals. However, AMPK opposes the effects of AKT1 and 
functions as an inhibitor of mTOR. AMPK is activated 
by an increased AMP/ATP ratio and is responsible for 
shifting cells to OXPHOS and inhibiting cell proliferation 
[37]. AMPK inhibits the activation of mTOR complex 
indirectly by mediating phosphorylation of the mTOR 
upstream regulator TSC2 to keep it suppressed [38] or 
directly via phosphorylation of the mTOR regulatory 
component, Raptor, to trigger its sequestration by 14-3-3 
and subsequent dissociation from mTOR [39]. In many 
types of cancer the liver kinase B1 (LKB1), the upstream 
activator for AMPK, is inactivated. This results in dimin-
ished AMPK signaling and loss of mTOR inhibition [37] 
and might support the shift of cancer cell metabolism 
towards glycolysis. Furthermore, loss of AMPK signaling 
mediates increased expression of hypoxia induced factor 
1α (HIF1α) [40].
Deregulation of the mTOR pathway is often observed 
in human cancers, which is consistent with its critical 
role in regulating cell growth and metabolism [36, 41]. 
The most prominent function of mTOR is to control pro-
tein synthesis through directly phosphorylating transla-
tional regulators such as eukaryotic translation initiation 
factor 4E binding protein 1 (4E-BP1) and S6 kinase 1 
(S6K1) [42]. By this mechanism, oncogenic mTOR trig-
gers protein synthesis and enhances cell growth and pro-
liferation. Consistently, mutations or loss-of-function of 
upstream regulatory genes, such as tuberous sclerosis 
complex 1/2 (TSC1/2), have been linked to cancer initia-
tion and development [43].
p53‑Myc
Although the transcription factor and tumor suppressor 
p53 is best known for its functions in the DNA damage 
response and apoptosis [44], it has become evident that 
p53 is also an important regulator of metabolism [45]. 
p53 inhibits the glycolytic pathway by upregulating the 
expression of TP53-induced glycolysis and apoptosis 
regulator (TIGAR), an enzyme that decreases the lev-
els of the glycolytic activator fructose-2,6-bisphosphate 
[46]. Moreover, p53 supports the expression of PTEN, 
which inhibits the PI3K pathway, and thus suppresses 
glycolysis [47]. In addition, p53 promotes OXPHOS by 
fostering expression of cytochrome C oxidase assembly 
protein (SCO2), which is required for the assembly of 
the cytochrome C oxidase complex of the electron trans-
port chain [48]. Consequently, besides its anti-apoptotic 
effect, the loss of p53 can be a major force behind the 
acquisition of the glycolytic phenotype of cancer cells 
[49, 50].
The transcription factor c-Myc has important meta-
bolic roles in enhancing glycolysis, mitochondrial gene 
expression, and mitochondrial biogenesis [51]. Tumors 
overexpressing Myc also have increased metabolic 
flux [52]. Myc enhances transcription of genes encod-
ing glucose transporters to increase glucose import and 
glycolytic genes including HK, phosphoglucose isomer-
ase, phosphofructokinase, glyceraldehyde-3-phosphate 
dehydrogenase, phosphoglycerate kinase, and enolase 
[53]. Myc also promotes nucleotide and amino acid syn-
thesis, both through direct transcriptional regulation 
and through increasing the synthesis of mitochondrial 
metabolite precursors [54]. The effects of Myc or onco-
genic PI3K signaling can be further pronounced by the 
simultaneous action of the two pathways [55]. Since Myc 
and mTOR are master regulators of protein synthesis, 
one could anticipate that Myc coordinates with mTOR. 
Indeed, Myc inhibits the mTOR repressor TSC2, thereby 
increasing mTOR activity to facilitate translation through 
S6K and 4E-BP phosphorylation [56]. mTOR can also 
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increase glutamine flux through S6K1-dependent c-Myc 
upregulation, which in turn increases glutaminase (GLS) 
activity [57].
Metabolic flux
The basic caveat of low efficiency-ATP-production 
through glycolysis is compensated by increase in meta-
bolic flux. The uptake of glucose in cancer cells is ele-
vated by increased expression of glucose transporters, 
e.g. Glut1 [58] and Glut4 [59]. Furthermore, glycolytic 
genes are up-regulated (e.g. HK) [53], amplified (e.g. 
HK2) [60], or alternatively spliced (e.g. PKM2) [61]. The 
latter two alterations preferentially impact the enzymatic 
activity of key enzymes. Thereby, cancer cells accelerate 
the glycolytic flux and compensate for the reduced effi-
cacy of aerobic glycolysis. Consequently, the net amount 
of ATP generated by aerobic glycolysis is even higher 
compared to OXPHOS.
Additionally, cancer cells benefit from aerobic gly-
colysis and altered glycolytic-enzymatic activities by an 
increased production of biosynthetic precursors. After 
the first reaction of glycolysis by HK2, glucose is phos-
phorylated to glucose-6-phosphate (G6P). A proportion 
of G6P can be redirected into the pentosphosphate path-
way (PPP) to generate NADPH and ribose 5-phosphate 
(R5P) [54]. NADPH itself is utilized for macromolecu-
lar biosynthesis and redox regulation [62]. R5P is also 
needed for nucleotide synthesis [62]. G6P may also be 
used in the hexosamine pathway, which provides the cell 
with Uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc), a co-substrate for protein glycosylation [63]. 
Another glycolysis product, 3-phosphoglycerate, feeds 
into the serine/glycine synthesis pathway fostering nucle-
otide and protein biosynthesis [64, 65].
Beyond Warburg
Metabolic adaptation of cancer cells extends beyond ATP 
production. Energy production is only one part of the 
growth equation. In parallel to energy generation, cancer 
cells require biosynthetic precursors in order to support 
their growth. Furthermore, because cancer cells gener-
ate reactive oxygen species (ROS) as a consequence of 
rapid proliferation, activation of mechanisms to sustain 
the balance of the intracellular redox level is a key com-
ponent of metabolic adaptation. To meet their demands 
for biosynthetic precursors and to minimize metabolic 
damage, cancer cells have acquired unique biochemi-
cal properties. These alterations support survival and 
growth programs, adaptation to various microenviron-
mental conditions with minimum damage, and survival 
under stress and limited nutrient availability. To achieve 
these properties, cancer cells adopt molecular and bio-
chemical programs, which facilitate nutrient utilization 
in a manner distinct from their normal counterparts. 
Such changes have major impact not only on cancer cells 
themselves by supporting their growth, but also generate 
metabolic products which alter the microenvironment 
and affect the fate and function of immune cells residing 
in the microenvironment of cancer.
Tryptophan
Tryptophan is an essential amino acid and has a key 
role in cell survival. The enzymes that initiate the first 
and rate-limiting step of tryptophan degradation to 
N-formylkynurenine during tryptophan catabolism in 
the kynurenine pathway are tryptophan 2,3-dioxygenase 
(TDO), indoleamine 2,3-dioxygenase 1 and 2 (IDO1 and 
IDO2, respectively) [66]. Although these enzymes cata-
lyze the same biochemical reaction, they share limited 
structural similarity [67]. It is noteworthy that tumor 
cells do not upregulate expression of TDO but specifi-
cally overexpress IDO, which recognizes a broader range 
of substrates, including l- or d-tryptophan, serotonin, 
and tryptamine [68]. This allows cancer cells to utilize 
a wider range of amino acids by altering the expression 
of a single gene. At the end of the kynurenine pathway 
quinolinic acid is generated [69]. In a subsequent step, 
NAD+, an essential cofactor for cellular homeostasis, 
can be produced from quinolinic acid [70–73]. Thus, 
IDO overexpression in tumor cells promotes de novo 
NAD+ synthesis. The underlying mechanism and sig-
nals causing IDO overexpression in cancer cells are cur-
rently under intense investigation. Although the precise 
mechanism(s) remain uncertain, there is preliminary evi-
dence that IFN-γ might be contributing to IDO expres-
sion in tumors [74].
Glutamine
Elevated glutamine consumption is another metabolic 
change characteristic of rapidly proliferating cells [75]. 
Interestingly, the increase glutamine demand of prolif-
erating cancer cells does not reflect an increase of the 
amino acid pool for protein synthesis [76]. Instead, rap-
idly proliferating cancer cells use glutamine for other 
important tasks, e.g. to synthesize anti-oxidative glu-
tathione, maintain cellular pools of NADPH, and fuel 
anaplerotic reactions to replenish tricarboxylic acid 
(TCA) cycle intermediates [76, 77]. Glutaminolysis is 
the process of glutamine conversion to glutamate by 
glutaminase (GLS) and, subsequently, to a-ketoglutar-
ate (a-KG), which enters the TCA cycle to contribute to 
amino acid, nucleotide, and fatty-acid biosynthesis. Glu-
taminolysis is elevated in cancer cells. In order to meet 
their increase needs for glutamine, cancer cells upregu-
late the glutamine transporter Solute Carrier Family 1 
member 5 (SLC1A5) in a Myc-dependent manner [78, 
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79]. In addition, oncogenic Myc increases glutamine 
uptake and the conversion of glutamine into a mitochon-
drial carbon source by promoting the expression of GLS 
[54]. Myc also promotes glutamine import by inducing 
the glutamine transporter ASCT2 [78]. The reliance on 
glutamine metabolism appears especially critical under 
metabolic stress conditions, particularly under glucose 
and oxygen deprivation. Interestingly, Myc overexpres-
sion has been shown to be sufficient to induce glutamine 
“addiction,” i.e. cancer cells dependence on glutamine 
metabolism for survival [80].
Besides the contribution to amino acid biosynthesis 
as basic building block for protein synthesis, glutamine 
has another role in the cancer cell, which involves pro-
tein translation. Abundant glutamine levels modulate 
mTORC1, a key regulator of protein translation [81]. In 
the presence of sufficient amounts of amino acids [Glu-
tamine and essential amino acids (EAA)], growth factor 
signaling through PI3K-Akt or the extracellular signal-
regulated kinase (ERK)-ribosomal protein S6 kinase 
(RSK) pathways activate mTORC1 [82]. A portion of the 
imported glutamine into cells is not utilized for anabolic 
metabolism but rather shuttled out of the cell in exchange 
for EAAs that can be used for protein synthesis. There-
fore, glutamine serves as precursor for protein synthesis, 
as an inducer of mTORC1 signaling, and as a source of 
EAAs to promote protein translation [82].
Redox status (ROS/NADPH/GSH/TRX)
The high metabolic activity of cancer cells results in ele-
vated ROS levels. Cancer cells develop several protec-
tive mechanisms to counteract the toxic effects of high 
ROS by increasing the production of metabolites that 
have reductive power. Amino acids can fuel macromol-
ecule production, but at the same time particular amino 
acids, i.e. glutamine, are utilized for the generation of 
NADPH. The cellular NADPH pool is also sustained by 
PPP, through IDH1/2-mediated conversion of isocitrate 
to αKG, and by ME1-mediated conversion of malate to 
pyruvate [10]. NADPH is either used as a cofactor or as a 
reducing agent. The latter function is of particular impor-
tance since rapidly proliferating cells produce ROS as 
byproduct in many anabolic processes. As a crucial anti-
oxidant, NADPH provides the reducing power for both 
the glutathione (GSH) and thioredoxin (TRX) systems 
that scavenge ROS and repair ROS-induced damage [83]. 
Glutamine through aKG serves the de novo production 
of GSH [84]. GSH reduces ROS by serving as an elec-
tron donor via its thiol group. During this process two 
molecules of glutathione are converted to the oxidized 
form, glutathione disulfide (GSSG). Once oxidized, GSSG 
can be reduced by glutathione reductase in a NADPH-
dependent manner [84]. Similar to GSH, thioredoxins 
act as antioxidants by mediating cysteine thiol-disulfide 
exchange. Oxidized thioredoxins are converted back to 
the reduced state by the NADPH-dependent flavoen-
zyme thioredoxin reductase [85]. Another mechanism 
by which cancer cells counteract elevated ROS levels is 
based on the transcription factor nuclear factor eryth-
roid 2-related factor 2 (NRF2) [86]. NRF2 is the master 
regulator of intracellular antioxidant responses. Hyperac-
tive PI3K signaling [87] as well as mutations in the NRF2 
gene [88] lead to the constitutive stabilization of NRF2 
causing expression of anti-oxidant genes like glutathione 
reductase [89, 90], thioredoxin [91], thioredoxin reduc-
tase 1 [89, 90], and others [86]. It is also noteworthy that 
in tumor cells NRF2 can enhance expression of genes 
involved in PPP such as glucose-6-phosphate dehydro-
genase, phosphogluconate dehydrogenase, transketolase, 
and transaldolase 1, which contribute to NADPH regen-
eration [92].
Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α) is a transcriptional coacti-
vator known as a key regulator of mitochondrial biogene-
sis and function [93]. Nevertheless, it was recently shown 
that PGC-1α is upregulated in melanoma and protects 
cancer cells from ROS by enhancing the expression of 
ROS detoxifying genes [94]. The guardian of the genome, 
p53, also contributes to the cellular ROS balancing [95]. 
However, the function of p53 in the generation and 
detoxification of ROS is complex and can have oppos-
ing effects. p53 may cause the generation of ROS by the 
induction of a gene cluster named PIG1–13 (p53-induc-
ible genes 1–13), which has strong pro-oxidant proper-
ties [96]. It is likely that this feature of p53 is related to 
its pro-apoptotic function. However, ROS are particularly 
potent in promoting DNA damage and p53-dependent 
ROS detoxification is part of the cellular DNA damage 
response. Upon ROS-mediated damage p53 enhances the 
transcription of several antioxidant genes [97], including 
Sestrins [98], glutathione peroxidase 1 (GPx1) [99], and 
TIGAR [46]. Therefore, the effect of p53 on balancing 
cellular ROS in cancer cells probably depends not only on 
the presence or absence of p53 but also on the particular 
mutation of p53, which might alter the preference of p53 
for the regulation of distinct target genes [100].
An additional mechanism for NADPH generation 
depends on pyruvate kinase (PK). PK catalyzes the rate-
limiting, ATP-generating step of glycolysis in which 
phosphoenolpyruvate is converted to pyruvate [101]. In 
cancer cells the M2 isoform (PKM2) is specifically upreg-
ulated. However, PKM2 is typically found in an inactive 
state and is less efficient in promoting glycolysis [102–
104]. Despite slowing glycolysis, PKM2 provides a growth 
advantage to cancer cells. PKM2 allows carbohydrate 
metabolites to enter other pathways, which generate 
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macromolecule precursors required for cell growth and 
reducing equivalents such as NADPH, which maintain 
redox balance [10]. At the molecular level, PKM2 can be 
regulated by oncogenes. Specifically, the oncogene c-Myc 
promotes PKM2 over PKM1 by modulating exon splic-
ing [105]. Additionally, PI3K and mTOR signaling can 
increase PKM2 expression through HIF1α-regulated 
transcription [106, 107]. In addition to glylcolysis, PKM2 
is also involved in regulating gene expression and cell 
cycle progression. Nuclear PKM2 can interact with 
β-catenin to enhance its activity, implicating PKM2 as a 
transcriptional co‐activator [108]. Furthermore, PKM2‐
dependent histone H3 phosphorylation can induce gene 
expression, cell proliferation and tumorigenesis [109, 
110].
Epigenetics
Epigenetic alterations are well-known causes for the 
onset of cancer. These include global genomic DNA 
hypomethylation, site-specific CpG island changes, as 
well as altered histone modifications and non-coding 
RNAs. Most of these changes can be caused by mutations 
in the enzymes involved in these processes. Nevertheless, 
epigenetic modifiers rely on cofactors to generate epige-
netic marks. These cofactors are generated via different 
cellular metabolic pathways. Therefore, one can imag-
ine that global deregulation of cellular metabolism can 
influence epigenetic enzymes by the amount of cofac-
tors present in a cell. Also, accumulation of inhibitory or 
activating molecules can change the enzymatic activity of 
epigenetic modifiers and consequently the cellular epig-
enome. For example, succinate, fumarate, and 2-hydrox-
yglutarate can inhibit the activity of histone and DNA 
demethylases (HDMs and DDMs) at high concentrations 
and can act as oncometabolites, i.e. metabolites that can 
promote tumorigenesis by altering the epigenome [111]. 
2-Hydroxyglutarate (2HG) is generated by mutated IDH 
and is commonly found in gliomas and acute myeloid 
leukaemia but not in the normal counterparts of these 
cancer cells [112]. These oncometabolites are structurally 
similar to their precursor metabolite, α-ketoglutarate. 
As a consequence, they act as competitive inhibitors for 
a superfamily of enzymes called the α-ketoglutarate-
dependent dioxygenases. These enzymes function in fatty 
acid metabolism, oxygen sensing, collagen biosynthesis, 
and modulation of the epigenome [113]. Several tumor 
types with succinate dehydrogenase (SDH) mutations 
have elevated levels of succinate and fumarate and have 
been identified to carry characteristic DNA hypermethyl-
ation patterns, which are due to reduced DDMs activity. 
Particularly, the DDM 10-11-translocation methylcyto-
sine dioxygenase (TET), which removes methyl groups in 
an αKG-dependent manner, is inhibited. Such alterations 
have been shown to be sufficient to drive oncogenesis 
[114, 115]. The jumunji-C HDMs are a major class of 
α-KG-dependent dioxygenases [116]. They initiate the 
removal of methyl groups from histones by hydroxylation 
and thus alter gene transcription. In tumors with IDH1/2 
mutations, high levels of fumarate, succinate, and 2HG 
have been reported, and these increases correlate with 
elevated histone methylation for H3K9 and H3K27, 
which are gene repressive marks [117].
Recent studies have shown that metabolic flux through 
the TCA cycle can affect gene transcription and/or epige-
netic programs. For example, TCA intermediates such as 
α-KG, succinate, and fumarate can directly or indirectly 
affect the activities of metabolic enzymes, transcription 
factors such as HIF1α, and epigenetic regulators such as 
histone demethylases [109, 118–120]. Interestingly, α-KG 
has also been involved in the maintenance of pluripo-
tency of embryonic stem (ES) cells by epigenetic mech-
anisms [121]. Moreover, in ES cells glucose availability 
and acetyl-CoA production can also influence epigenet-
ics by regulating the cytosolic acetyl-CoA pool available 
for histone acetylation reactions [122, 123], raising the 
possibility that such mechanisms might be operable in 
cancer and particularly in cancer initiating cells, which 
have stem cell-like properties. Epigenetic regulation of 
gene expression and function via altering histone/DNA 
methylation and acetylation levels and their therapeutic 
targeting is currently a rapidly developing field and will 
likely provide new opportunities to target the conse-
quences of metabolic reprograming in tumors and poten-
tially immune cells.
Changes in the microenvironment
All the above-mentioned intracellular metabolic pro-
cesses, which are altered in cancer cells, affect the tumor 
microenvironment by several means. The consequences 
of such changes have significant impact on cancer cells 
as well as non-cancerous cells present in the tumor 
microenvironment.
Hypoxia
Hypoxia arises in tumors through the uncontrolled pro-
liferation of cancer cells. Due to the rapid proliferation 
and lack of sufficient vascularization, cancer cells quickly 
exhaust the oxygen (and nutrient) supply from the nor-
mal vasculature and create a hypoxic microenvironment 
[124]. Under these conditions the adaptation to glyco-
lysis described above provides a strong selective growth 
advantage of tumor cells over non-tumor cells. Under 
hypoxic conditions the transcription factor HIF1α is sta-
bilized [125]. Moreover, the oncogene-activated PI3K 
pathway can also stabilize HIF1α, even under normoxic 
conditions [126, 127]. Upon activation, HIF1α triggers 
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transcription of glucose transporters and glycolytic genes 
[128]. HIF1α can also decrease the rate of OXPHOS by 
reducing the flux of pyruvate into the TCA cycle through 
fostering transcription of pyruvate dehydrogenase 
kinases [129, 130]. It is of note that under physiological 
conditions HIF1 can inhibit the activity of Myc. Never-
theless, oncogenic Myc collaborates with HIF to augment 
aerobic glycolysis [131]. It has been found that high levels 
of Myc bind to a new set of target genes, suggesting that 
the behavior of Myc depends on its level [132, 133].
Nutrient deprivation
In addition to the deprivation of oxygen, the fast growing 
cancer cells also consume most nutrients from the sur-
rounding. High demand for energy and anabolic metab-
olism, increased import, and fast metabolic flux cause 
nutrient deprivation to other cells residing in the same 
niche. Besides its direct effect on metabolism, nutrient 
deprivation causes endoplasmic reticulum (ER) stress 
in the microenvironment. In order to counteract the ER 
stress-associated damages, several cellular processes, 
collectively named “unfolded protein response” (UPR), 
are activated. The UPR has a dual function: it attenuates 
ER-associated damage, and if this is not feasible, it acti-
vates apoptosis [134]. Additionally, nutrient deprivation 
can cause autophagy, which is a highly regulated process 
involving lysosomal degradation of intracellular compo-
nents, damaged organelles, misfolded proteins, and toxic 
aggregates. Autophagy can be induced in response to 
various conditions, including nutrient deprivation, meta-
bolic stress, and hypoxia to adapt cellular conditions for 
survival. However, extensive autophagy-based degrada-
tion pathways may cause autophagy-associated cell death 
[135]. Thus, cells in the microenvironment are challenged 
by the cell-death-inducing effects of nutrient deprivation.
Metabolic waste
As a consequence of their high metabolic rate, tumor 
cells generate high amounts of metabolic “waste,” which 
is transported out of the cell. Accumulation of these 
products creates a harsh and potentially metabolically 
toxic environment. For example, increasing amounts 
of lactate acidify the microenvironment. Interestingly, 
cancer cells can consume lactate as a metabolic fuel and 
utilize it through conversion back to pyruvate and sub-
sequent oxidation to provide a fuel in times of nutrient 
depletion [136]. Various downstream metabolites gener-
ated following tryptophan breakdown are also released 
by cancer cells into the microenvironment. Cells in the 
tumor microenvironment take up kynurenine (Kyn) via 
the amino acid transporter LAT1. Subsequently, Kyn 
binds to the aryl hydrocarbon receptor (AhR), which 
translocates from the cytoplasm to the nucleus, where 
it can drive expression of various genes [73]. Kynurenic 
acid can enter cells via the human organic anion trans-
porters hOAT1 and hOAT3 [137–139]. Quinolinic acid 
is an N-methyl-d-aspartate receptor agonist, whereas 
kynurenic acid is an antagonist of this receptor [140]. 
These findings suggest that tryptophan-derived metab-
olites can affect functionality of cells in the tumor 
microenvironment. The hypoxic, acidified, and nutrient-
deprived environment causes metabolic stress to neigh-
boring non-malignant cells and acts as a barrier shielding 
the tumor from any impact mediated by tumor-specific T 
effector cells residing or recruited in the tumor microen-
vironment (Fig. 2).
Basic metabolic features of T cells
Naïve T cells have low metabolic requirements and 
depend predominantly on the utilization of low amounts 
of various nutrients including glucose, fatty acids, and 
amino acids, as well as on pyruvate and glutamine oxida-
tion via the TCA cycle (Fig. 3). In order to maintain this 
basal energy-generating metabolism to support their con-
tinuous migration through secondary lymphoid tissues 
and immune surveillance, naïve T cells require cell extrin-
sic signals such as IL-7 [9, 141]. Upon antigen encounter 
there is a dynamic change on T cell metabolism charac-
terized by extensive proliferation and differentiation into 
effector T cells (TEFF). TCR-mediated signaling promotes 
the upregulation of glucose and amino acid transporters 
at the T cell surface and directs the metabolic reprogram-
ming of naïve T cells from OXPHOS to glycolysis, which 
is mandatory for the acquisition of T cell effector differ-
entiation and function [9, 142]. During the subsequent 
stages of T cell response, when the pathogen is cleared, 
most Teff cells undergo cell death resulting in a dramatic 
reduction of antigen-specific Teff -a process known as 
contraction phase- leaving behind a small population of 
antigen-specific T cells, which survive this demise and 
become T memory cells (Tm). Tm cells display a charac-
teristic increase in mitochondrial mass and thus a greater 
mitochondrial spare respiratory capacity (SRC) [9, 143, 
144], which is the maximal mitochondrial respiratory 
capacity available to a cell to produce energy under con-
ditions of increased work or stress.
For energy generation, Tm cells rely on β-oxidation 
of de novo generated fatty acids that have been synthe-
sized from glucose during the effector phase by fatty acid 
synthesis and have been stored intracellularly, instead of 
uptaking and using extracellular lipids [145]. Interest-
ingly, for membrane biosynthesis, lymphocytes also rely 
on de novo generated free fatty acids from glucose and 
glutamine, despite the availability of extracellular lipids 
[145–147]. In contrast to the dominant role of fatty acid 
oxidation (FAO) in memory cells for energy generation, 
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FAO and other ATP-generating catabolic pathways 
are actively suppressed in Teff cells. A key mechanism 
responsible for this outcome is mediated by the transcrip-
tion factor Myc, which is induced during T cell activation 
and has a dominant role in driving metabolic repro-
gramming by promoting glycolysis and glutaminolysis 
and suppressing FAO and other ATP-generating cata-
bolic pathway [148]. Importantly, Myc also has a role in 
the fate of T cells after division, which is induced during 
encounter of T cell with APC [149]. Specifically, upon 
activation by antigen-presenting cells (APCs), T cells can 
undergo asymmetric cell division, wherein the daughter 
Fig. 2 Cancer cells induce several metabolic changes in the microenvironment. The increased uptake of nutrients such as glucose and amino 
acids depletes these resources for non-tumor cells. This can inhibit the growth and function of non-tumor cells in the microenvironment due to 
the lack of resources for cellular metabolism. Moreover, nutrient depletion can lead to autophagy, ER-stress, and, finally, to cell death. Cancer cells 
also generate a hypoxic microenvironment. The prolonged lack of oxygen inhibits regular cell function in non-tumor cells, whereas in cancer cells 
hypoxia (in combination with oncogenic PI3K signaling) stabilizes HIF1α and promotes the glycolytic phenotype. Additionally, HIF1α enhances 
expression of PDL-1, which can engage with PD-1 on other cancer cells in the microenvironment. This activates mTOR signaling and supports tumor 
growth, whereas engagement of PD-1 in T cells inhibits T cell activation and growth. Thereby, cancer cells can spread an inter-cancer-cell growth 
signal, while suppressing responses of tumor-infiltrating T cells. The increased metabolic activity of cancer cells produces waste byproducts, like 
lactate and tryptophan metabolites, which are secreted to the microenvironment and act inhibitory on non-tumor cells. Lactate not only acidifies 
the microenvironment resulting in inhibition of the surrounding non-tumor cells, but can also be re-imported into cancer cells and can be used to 
feed into glycolysis
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cell proximal to the APC is more likely to differentiate 
into an effector-like T cell and the distal daughter is more 
likely to differentiate into a memory-like T cell [150]. 
Myc has an active role in regulating the asymmetric dis-
tribution of amino acid transporters, amino acid content 
and mTORC1, which also correlated with an asymmetric 
glycolytic metabolic phenotype between the two daugh-
ter cells. Thus, Myc regulates metabolic programs not 
only at the early stages of T cell activation but also after 
daughter cell division.
Under sufficient energy conditions, intermediate 
metabolites of glycolysis can be used in the PPP to sup-
port nucleotide biosynthesis and NADPH production 
important for anabolic pathways and redox control. 
Moreover, glycolytic enzymes have been linked directly 
to the regulation of T cell function. For example, when 
not engaged in glycolysis, the glycolytic enzyme glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) binds 
to AU-rich elements within the 3′ UTR of IFN-γ mRNA 
and prevents translation of IFN-γ mRNA, thereby 
Fig. 3 T cell differentiation is accompanied by metabolic changes, which can be affected by the tumor microenvironment altering their fate and 
function. a Naïve T cells function in antigenic surveillance and do not proliferate. This requires minimal energetic and biosynthetic activity which is 
represented by a metabolically quiescent state which is accompanied by minimal nutrient uptake. The only energy-demanding processes are ion 
homeostasis, membrane integrity, and movement. The primary ATP sources are OXPHOS and FAO to fuel the low energy demand. IL-7 signaling 
and activation of PI3K-Akt1-mTOR is required for survival and basal, low level Glut1 expression. (Furthermore, naïve T cells express low levels of both 
isoforms of PKM1 and PKM2 keeping PKM2 oncogenic function in check. Low quantities of pyruvate and glutamine are utilized in the TCA cycle. 
b Upon antigen encounter T cells differentiate into effector cells. This process is accompanied by metabolic changes which are required to fulfill 
the new effector functions and rapid proliferation. Antigen binding to the TCR and co-activation by CD28 inhibits FAO and activates PI3K-Akt1. 
This activation triggers glycolytic enzymes HK and PFK2. Additionally, mTOR signaling is turned on which enhances expression of glycolytic genes, 
glucose, and amino acid transporters via activation of transcription factors HIF1α and Myc. Effector T cells also switch from balanced PKM1 and 
PKM2 expression to increased and predominant expression of PKM2, which promotes generation of biosynthetic precursors. Additionally, the SRC 
is decreased and the uptake of nutrients is enhanced. These events promote the establishment of a glycolytic phenotype with increased glutami-
nolysis combined with a high degree of protein, lipid, and nucleic acid synthesis to support cell growth and proliferation. c After antigen challenge 
most effector T cells undergo apoptosis during the contraction phase. A small proportion differentiates into memory T cells with prolonged survival 
capacity to provide long-term antigenic memory. Memory T cells do not proliferate and thus have minimal biosynthesis and nutrient uptake. How-
ever, they show increased SRC, which supports their ability to rapidly proliferate upon re-encounter of antigen. This cellular fate includes another 
metabolic adaption. In particular, metabolic switch to FAO via increased CPT1 expression and elevated AMPK activity, which represses HIF1α, mTOR, 
and Myc. Thereby, AMPK inhibits glycolysis, which was the primary ATP source during the effector phase. Extracellular queues that support memory 
cell formation -such as IL-15- promote these metabolic changes. Naïve T cells can differentiate into different subsets of specialized T cells mainly 
depending on extracellular stimuli and factors. The tumor microenvironment influences these cell fate decisions in a metabolic manner. The lack 
of glucose, amino acids, and oxygen as well as the accumulation of metabolic byproducts secreted to the microenvironment generate a milieu 
that suppresses glycolysis-dependent T cell fates like CD8+ T effector cells and CD4+ Th1/2/17. In contrast, FAO-related cell fates such as CD8+ T 
cell memory and CD4+ T regulatory cells are promoted. Especially, amino acid depletion supports formation of immunosuppressive macrophages. 
Taken together, the tumor microenvironment generates an immunosuppressive milieu that fosters immune evasion
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suppressing IFN-γ production [19]. Another example 
involves the glycolytic enzyme pyruvate kinase (PK), 
which catalyzes the conversion of phosphoenolpyruvate 
(PEP) to pyruvate during glycolysis. Differential splicing 
generates two isoforms, M1 or M2. With the PKM2 splice 
variant being expressed in embryonic tissues, proliferat-
ing cells, and tumor cells PKM2 coordinates glycolytic 
flux and cell proliferation [61, 104]. Because the M2 iso-
form is less efficient in converting PEP to pyruvate than 
the M1 isoform, it has been suggested that this property 
slows down glycolysis towards lactate but skews glyco-
lysis towards biosynthetic pathways, thus giving cells a 
growth advantage [151]. Resting naïve T cells express 
both M1 and M2 isoforms, while mitogen activation pro-
motes the rapid accumulation of the M2 isoform, which 
becomes the dominant isoform expressed in Teff cells 
[152, 153]. In addition, despite its relatively low affinity 
for PEP, dimeric PKM2 is able to use PEP as a phosphate 
donor and catalyzes the in vitro phosphorylation of some 
protein targets, including the transcription factor STAT3.
Role of metabolism in T cell differentiation
Many recent studies have shown that distinct T cell fates 
can be imprinted in divergent metabolic programs. For 
example, the metabolism-cell fate connection has been 
shown with the switch to glycolysis that accompanies 
Teff differentiation and the switch to FAO that accom-
panies the conversion of Teff to Tm [154]. Also, enforc-
ing FAO by elevating AMPK activity or by inhibiting 
mTOR results in increased numbers of Tm cells [154, 
155], which are capable of regenerating the specific T cell 
clone upon encounter with the same antigen. This ability 
of memory T cells for clone regeneration is reminiscent 
of the properties of the very small fraction of OXPHOS-
dependent cancer cells with stemness features, which 
resides within the tumors, as mentioned above. In addi-
tion, conversion toward a T regulatory (Treg) phenotype 
is also favored in conditions of increased OXPHOS and 
decreased glycolysis. Although pronounced differences 
have been established between the metabolic programs 
of Teff and Treg cells, distinct metabolic differences 
within the various Teff subsets have not yet been discov-
ered. At the metabolic level, Teff cells Th1, Th2, and Th17 
cells and Treg are the best-defined CD4+ T cell subsets. 
It is well known that a variety of cytokines can determine 
the differentiation fate of T cell subsets [156–160], and 
it is becoming increasingly clear that metabolism plays 
a significant role in driving these distinct differentiation 
programs. For example, there is a strong bias toward gly-
colysis over mitochondrial metabolism by proinflamma-
tory CD4+ Th1, Th2, and Th17 lineages whereas induced 
CD4+ Treg lineage cells display a mixed metabolism 
involving glycolysis, lipid oxidation, and OXPHOS [18]. It 
is noteworthy that blockade of glycolysis during in vitro 
Th17 differentiation favors Treg formation rather than 
Th17 cells [161]. Addition of exogenous fatty acids (FAs) 
in the culture of T cells activated under skewing condi-
tions strongly inhibits the production of Th1, Th2, and 
Th17 cytokines, but not the Treg suppressive function. 
Importantly, inhibition of Teff function in the presence of 
FAs cannot be rescued by re-addition of Th1-, Th2-, and 
Th17-promoting cytokines [18].
Effects of the tumor microenvironment on T cell 
fitness
Exhaustion
T cell “metabolic fitness” is central to effective antitumor 
immunity but is compromised by unique conditions of 
limited nutrient availability in the tumor nutrient micro-
environment and the effects of immune checkpoints 
[162]. Within the immune suppressive tumor microen-
vironment, T cells acquire an “exhausted” phenotype, 
which is characterized by progressive loss of effector 
functions, changes in expression and function of key 
transcription factors, and metabolic alterations. In addi-
tion “exhausted” T cells are characterized by a sustained 
upregulation and co-expression of multiple inhibitory 
receptors [163, 164]. The multiple metabolic constraints 
imposed by the cancer cell metabolism in the tumor 
microenvironment minimize the potential of T cells to 
mediate effector function. It is likely that nutrient avail-
ability, effects of inhibitory receptors and metabolic 
changes of the microenvironment drive T cell differen-
tiation to the state of exhaustion. T cells receiving signals 
through the key inhibitory receptor PD-1 are switched 
to low glycolytic and low OXPHOS state with limited 
biosynthetic activity and low antioxidant reserves [15]. 
It is likely that such changes in metabolic reprogram-
ming drive T cell differentiation to the state of exhaus-
tion. T cell exhaustion is an active process and can lead to 
measurable consequences on T cell function. For exam-
ple, distinct subsets of exhausted T cells exist with dif-
ferent potentials for recovering function after blockade 
of the PD-1 pathway. Exhausted T cells with intermedi-
ate expression of PD-1 (PD-1int) can be reinvigorated by 
blockade of the PD-1 pathway, whereas those with high 
expression of PD-1 (PD-1high cells) cannot [163, 164]. 
These distinct subsets of exhausted T cells may also have 
different bioenergetic properties and differential capacity 
for mitochondrial biogenesis. It is tempting to speculate 
that the degree of exhaustion and the ability to reinvig-
orate exhausted T cells might depend on the reserve of 
lipids, which appear to be the only source of energy gen-
eration by FAO in T cells receiving PD-1 signals [15]. It 
is also possible that blockade of the PD-1: PD-L1 path-
way may lead to transient regeneration of Teff cells if the 
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metabolic defects of exhausted tumor-specific T cells are 
not fully recovered. Thus, identification of the distinct 
bioenergetic profiles in exhausted T cell subsets might 
provide new tools to determine the level of T cell exhaus-
tion and also identify novel targets to reverse exhaustion 
in addition to PD-1 blockade.
Nutrients
The main nutrients that support survival and growth of 
T lymphocytes are glucose, amino acids, and lipids, and 
their deprivation results in impaired T cell function. 
Depending on the type of nutrients present, T cells can 
acquire distinct differentiation program and functional 
fate [21, 165, 166]. In the tumor microenvironment can-
cer and T cells develop metabolic competition for the 
utilization of available nutrients among which glucose 
has a central role. Cancer cells are addicted to a steady 
state glycolysis, whereas T cells depend on glucose dur-
ing the process of antigen-mediated activation that leads 
to expansion and development of effector functions. 
Limiting glucose in the culture decreases the activation 
of naïve T cells and the production of effector cytokines 
although a significant degree of proliferation might be 
preserved through OXPHOS [19, 148, 167–172]. Mecha-
nistically, glycolysis might promote IFN-γ production by 
inducing GAPDH activation and releasing GAPDH from 
binding at the 3′UTR of the IFN-γ promoter, thereby 
inducing IFN-γ production via post- transciptional 
mechanisms [19]. In addition, the glycolytic metabolite 
phosphoenolpyruvate (PEP) promotes T cell activation 
by sustaining T cell receptor-mediated Ca2+-NFAT sign-
aling and effector functions due to repressing sarco/ER 
Ca2+-ATPase (SERCA) activity [17]. Because glycolysis is 
intimately linked with T effector differentiation, glucose 
deprivation due to high glucose flux in the cancer cells 
results in limited glucose availability for utilization by 
T cells. As a consequence, T cells not only are unable to 
develop tumoricidal effector functions but also alter their 
differentiation program resulting in the generation of cell 
types that develop during limited glucose supplies, such 
as Treg and T exhausted T cells [15, 18].
T cells also activate glutamine transport and catabo-
lism mechanisms during their stimulation [167–169]. 
Glutamine has an essential role to support the TCA 
cycle through anaplerosis after prior conversion to glu-
tamate and aKG and is also critical for ATP production 
via OXPHOS even in presence of glucose [20]. Gluta-
mate also serves as a key component for glutathione 
(GSH) synthesis and antioxidant defense [173]. Similarly 
to glucose, cancer cells use glutamine for their metabolic 
needs [174] indicating that competition for glutamine 
utilization by cancer and T cells also occurs in the tumor 
microenvironment. Therapeutic targeting of glutamine 
metabolism by glutaminase inhibitors in cancer cells is 
currently under investigation in clinical trials for hema-
tologic malignancies and solid tumors (https://www.
clinicaltrials.gov/). It remains to be determined how such 
therapeutic approaches will affect T cell differentiation 
and function.
Decreased levels of the essential amino acid, l-trypto-
phan, can be caused by overexpression of IDO on tumor 
cells [175, 176]. It is well documented from studies in 
mouse models and patients that IDO expressed in can-
cer cells or DC in the cancer microenvironment medi-
ates immunosuppressive effects and tolerance to tumor 
via mechanisms independent from l-tryptophan dep-
rivation [177, 178]. Detailed recent studies designed to 
delineate the mechanisms of tumor cell IDO-induced 
immunosuppression showed that the effect of IDO 
in the tumor microenvironment is mediated through 
increased differentiation of Treg cells at the tumor site, 
systemic expansion of myeloid cells and marked recruit-
ment of myeloid-derived suppressor cells (MDSCs) into 
the tumor microenvironment [179]. Such correlation 
between IDO expression and MDSC infiltration has 
been identified not only in experimental animal models 
but also in samples from human patients with melanoma 
[179]. Metabolic competition and nutrient deprivation, 
accumulation of metabolic byproducts, effects of IDO act 
in concert with microenvironmental changes induced by 
hypoxia and tumor aerobic glycolysis to form a barrier to 
antitumor T cell immunity.
Lactate
Lactic acid is largely produced by highly glycolytic can-
cer cells and can suppress the proliferation and cytokine 
production of human cytotoxic T lymphocytes (CTLs) 
and reduce cytotoxic activity [180, 181]. Activated T 
cells also secrete lactate but, due to their higher meta-
bolic rate, cancer cells are most likely the key source of 
lactate in the tumor microenvironment. Moreover, since 
PD-1 ligation results in suppression of glycolysis and 
diminished lactate production [15], engagement of PD-1 
in T cells, in the context of cancer, will mitigate glycoly-
sis and production of lactate. Thus, the main source of 
lactate is the tumor, and eliminating lactate production 
by tumor cells would be anticipated to improve T cell 
mediated antitumor immunity. A major consequence 
of lactate secretion is microenvironmental acidifica-
tion. Studies that have addressed the role of acidic pH 
on immune function in the context of tumor have mostly 
focused on the impact of lactate-mediated acidification 
on macrophage polarization to the M2 suppressive phe-
notype [182]. However, lactate-mediated acidification 
can also induce Arginase 1, which promotes the deple-
tion of extracellular arginine levels, resulting in inhibition 
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of efficient T cell proliferation and activation [182, 183]. 
Moreover, manipulation of the pH of the tumor micro-
environment by the use of proton pump inhibitors results 
in less dysfunctional tumor infiltrating lymphocytes and 
increased therapeutic efficacy of both active and adop-
tive immunotherapy [184]. Despite its negative impacts 
on the immune cells, certain cancer cell types can utilize 
lactate itself as a metabolic fuel through reverse conver-
sion to pyruvate that is subsequently oxidized to provide 
a fuel in times of nutrient depletion [136]. The extent to 
which T cells can oxidize lactate is unknown. It is also 
unknown whether such biochemical pathway might 
impact selectively on Teff, Tm, or Treg differentiation 
and/or function.
Hypoxia
Hypoxia occurs physiologically in the microenviron-
ment of primary lymphoid organs, bone marrow, and 
thymus [185, 186] and plays a critical role in immune 
cell function and development [187, 188]. However, most 
prevalently, hypoxia is the hallmark of tissue microenvi-
ronments under pathological conditions as in the cases 
of cancer, inflammation, infection, necrosis, and auto-
immunity. Under the survival- and growth-unfavorable 
conditions of the hypoxic microenvironment, all cells, 
including T lymphocytes, need to adapt metabolic pro-
grams that support their survival [148, 189, 190]. Hypoxia 
inducible factors (HIFs) are the main transcription fac-
tors that sense and respond to hypoxia with HIF-1α and 
HIF-2α being the most widely studied members [191]. 
The activity of HIFs is regulated by post-transcriptional 
modifications, which involve the hydroxylation of their 
proline and asparagine residues prolyl hydroxylases [192]. 
The von Hippel–Lindau tumor suppressor (VHL) protein 
binds to hydroxylated HIF1α targeting it for ubiquitina-
tion and degradation by the proteasome. In normoxic 
conditions, hydroxylation and proteasomal degradation 
of HIF1α subunits take place, whereas under hypoxic 
conditions the hydroxylases are no longer active, allowing 
HIF1α to translocate to the nucleus and bind to HIF1β in 
order to regulate the transcription [193].
The hypoxia response, which is based on the function 
of the HIF1α and HIF2α transcription factors, upregu-
lates glucose transporters and multiple enzymes of the 
glycolytic pathway [128, 194]. In contrast, HIFs nega-
tively regulate TCA and OXPHOS regulatory genes. 
In renal carcinoma cells lacking VHL protein, the main 
negative regulator of HIFs, HIF1 negatively regulates 
mitochondrial biogenesis and oxygen consumption by 
inhibiting the activity of c-Myc [195]. Similarly to its 
effect in tumor cells, HIF1α mediates the metabolic 
switch from OXPHOS to aerobic glycolysis in lympho-
cytes [161] and directly regulates the Th17/Treg balance 
in favor of Th17 cells [196]. HIF1-deficient T cells display 
a marked reduction in the expression of IL-17 and Th17-
signature genes. Moreover, mice with HIF1α-deficient 
T cells are resistant to induction of Th17-dependent 
experimental autoimmune encephalitis, and this out-
come is associated with diminished Th17 and increased 
Treg differentiation [196]. HIF1α activates Th17 devel-
opment through RORγt and p300, and also attenuates 
Treg development by targeting Foxp3 for proteasomal 
degradation [161]. As a consequence, blocking glyco-
lysis during Th17 cell differentiation reduces the devel-
opment of Th17 cells and favors Treg formation [161], 
suggesting a direct link between metabolism and T cell 
fate determination. Conversely, deletion of VHL, which 
leads to elevated levels of HIFs, results in differentiation 
of cytotoxic CD8+ lymphocytes (CTLs) with a high gly-
colytic and low OXPHOS activity and, thus, favors the 
differentiation of effector CD8+ T cells [197]. It is a sub-
ject of active investigation how HIF1α affects memory 
formation and anti-tumor immunity. Importantly, loss 
of HIF1β alters expression of chemokines and receptors 
involved in migration and extravasation. Loss of HIF1β 
results in sustained CD62L expression and increased of 
T cell homing to secondary lymphoid organs. In addition, 
loss of HIF1β results in upregulation of CXCR3, CCR5, 
and CCR7 in CD8+ T cells [198]. Moreover, hypoxia may 
protect tumor cells from antitumor immunity and can 
promote HIF1α-dependent transcriptional upregulation 
of PD-L1 on cancer cells and myeloid-derived suppressor 
cells (MDSCs) that may inhibit PD-1-expressing T cells 
[199, 200]. Indeed, tumor cells have greater resistance to 
T cell-mediated killing under hypoxic conditions [200]. 
Thus, hypoxia affects both tumor and T cells and shapes 
the expression of critical transcription factors, effector 
molecules, chemokines, chemokine receptors, costimula-
tory receptors, and activation-induced inhibitory recep-
tors in a HIF-dependent manner. Therapeutic strategies 
targeting HIFs in the immune system might be beneficial 
for anti-tumor immunity.
Reactive oxygen species
Besides being considered as harmful by-products of 
metabolism or weapons of phagocytes against pathogens, 
ROS can also serve as signaling messengers in a multitude 
of pathways. It has also become evident that the source, 
kinetics and localization of ROS production all influ-
ence cell responses [201–204]. Tumors are influenced by 
changes in ROS production, and previous reports actu-
ally indicate that cancer cells exhibit more oxidative stress 
than their healthy counterparts [205]. In particular, mito-
chondria-derived ROS are essential for Kras-mediated 
cancer cell growth [5]. In contrast, other studies showed 
that inhibition or abrogation of LDH-A causes a shift to 
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higher OCR and ROS production from the mitochondria 
that render the tumor cells more susceptible to apopto-
sis [206, 207]. Moreover, it has been shown that increase 
in intracellular concentrations of ROS causes inhibition 
of the glycolytic enzyme PKM2 leading to glucose diver-
sion into the PPP, thereby generating sufficient reducing 
power for detoxification of ROS [208]. In a recent article 
by James Watson, co-discoverer of the double helix struc-
ture of DNA, it was pointed out that causing oxidative 
stress by targeting highly expressed antioxidant enzymes, 
which are not present in non-malignant cells, holds great 
promise as a strategy for finding novel anti-tumor drugs. 
In contrast, antioxidants seem to promote tumor survival 
and growth [209]. Interestingly, cultured colorectal cancer 
cells (CRC) harboring KRAS or BRAF mutations, which 
upregulate the glucose transporter Glut1, are selectively 
killed when exposed to high levels of vitamin C, but this is 
not due to the antioxidant function of vitamin C. Instead, 
this effect is mediated by the increased uptake of the oxi-
dized form of vitamin C, dehydroascorbate (DHA) via the 
Glut1 glucose transporter, which is subsequently reduced 
to vitamin C, thereby depleting glutathione and causing 
oxidative stress. Thus, in cancer cells ROS accumulates 
and inactivates GAPDH leading to an energetic crisis and 
cell death not seen in CRC cells not harboring KRAS and 
BRAF mutations [210].
In T cells, ROS can be derived from the catalytic 
activity of NADPH oxidase 2 (NOX-2), which is a cata-
lytic subunit of phagocyte oxidase (PHOX) expressed in 
the plasma membrane of T cells, or from dual oxidase 
I (DUOX-1), which is a cytoplasmic non-phagocytic 
isoform of NADPH oxidase [204, 211]. ROS can be 
generated from the electron transport chain of mito-
chondria [212, 213] as well as by lipoxygenases [214]. 
T cell activation is paralleled by transient generation of 
low, physiologically relevant levels of ROS, which facili-
tates activation of ROS-dependent transcription fac-
tors, NF-kB and AP-1 [215, 216]. This oxidative signal 
is indispensable for T cell activation. Together with a 
Ca2+ influx, it constitutes the minimal requirement for 
activation-induced gene expression (e.g., interleukin 2 
[IL-2], IL-4, CD95 ligand) [203]. In contrast to the indis-
pensable role of low ROS levels in T cell activation, pro-
longed exposure to high ROS concentrations can inhibit 
T cell proliferation and lead to apoptosis [217]. In addi-
tion, incubation of T cells with reactive nitrogen spe-
cies (RNS) such as peroxynitrite can inhibit proliferation 
[218]. Oxidative stress-induced modification to selective 
molecules involved in T cell receptor (TCR) signaling can 
render T cells hyporesponsive to activating stimuli [219]. 
The redox environment also affects T cell differentiation. 
Peripheral blood mononuclear cells (PBMC), stimulated 
with a ROS generator promoted Th2 and inhibited Th1 
differentiation [220]. Moreover, products of lipid peroxi-
dation, such as 4-hydroxy-2-nonenal (4HNE) and malo-
nyldialdehyde (MDA), promote differentiation towards 
a Th2 phenotype [221]. Interestingly, NOX-2 deficiency 
leads to differentiation towards the Th17 lineage [222]. 
Since ROS can affect critical metabolism-related T cell 
signaling pathways such as the MAPKs and Akt pathways 
[204], it is not unexpected that ROS would directly affect 
T cell differentiation and function. A study of the novel 
mechanism of Treg-mediated suppression by extracellu-
lar redox remodeling showed that murine Tregs suppress 
GSH synthesis and cysteine release by DCs in a CTLA-
4-dependent manner, leading to the oxidation of surface 
thiols, decrease in the major cellular antioxidant GSH, 
and reduced proliferation of conventional T cells [223, 
224]. Vitamin C, a naturally occurring antioxidant, can 
facilitate demethylation of Foxp3 enhancer and thus pro-
mote Treg generation [225].
In a recent work from our group, metabolite analysis of 
T cells in the presence of the checkpoint inhibitor PD-1 
showed that PD-1 ligation resulted in significantly more 
pronounced decrease in the levels of reduced GSH. How-
ever, T cells receiving PD-1 signals displayed higher levels 
of cysteine-GSH disulfide and ophthtalmate, a GSH-like 
product synthesized by the same enzymes. These changes 
indicate a higher attempt to increase GSH synthesis, 
which, together with the more pronounced decrease in 
the levels of reduced GSH, are suggestive of a more oxi-
dative environment in T cells receiving PD-1 signals [15]. 
Consistent with a role of PD-1 in generating a more oxi-
dative environment, another study showed that, follow-
ing allogeneic bone marrow transplantation, alloreactive 
T cells simultaneously upregulated PD-1 expression and 
ROS production derived by FAO, resulting in higher sus-
ceptibility to metabolic inhibition by F1F0-ATP synthase 
complex inhibitors, and this event could be reversed by 
antioxidants. In that context, PD-1-blockade decreased 
mitochondrial H2O2 and total cellular ROS levels as well 
as the efficacy of ROS-dependent inhibitory modulation 
of F1F0-ATP synthase complex [226]. Although high ROS 
is toxic for T cells as it induces oxidative metabolic dam-
age to various biochemical substrates, it should be noted 
that moderate levels of ROS have an indispensable role 
on T cell activation. The important involvement of ROS 
to T cell metabolic fate and function was highlighted by 
the recent identification of lymphocyte expansion mole-
cule (LEM). LEM has no effects on glycolysis but controls 
the levels of OXPHOS complexes and respiration, result-
ing in the production of pro-proliferative mitochondrial 
ROS, which is critical for promoting antigen-dependent 
CD8+ T cell proliferation, effector function, and long-
term protective memory cells in response to infection 
with lymphocytic choriomeningitis virus [227].
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Based on the above, it is not evident whether the use of 
antioxidants or oxidants would be a beneficial therapeu-
tic approach in the context of cancer. Caution should be 
exercised since such interventions will, most likely, also 
modulate T cell responses in addition to targeting cancer 
cells. One potential approach would be to target antioxi-
dant genes in cancer in order to suppress the antioxidant 
defense mechanisms and make them susceptible to ROS-
mediated apoptosis. Considering the fact that ROS are 
beneficial for T cell activation, a fine balance should be 
achieved in order to maximize anti-tumor effects without 
compromising T cell function.
Checkpoint inhibitors
During the past 5 years, cancer immunotherapy based on 
therapeutic targeting of checkpoint pathways has become 
a field of broad interest. This approach is based on the 
properties of T cells, which require at least two signals 
for activation. The first signal is mediated through TCR 
by recognition of specific antigen presented by the major 
histocompatibility complex (MHC) on antigen presenting 
cells (APCs). The second signal is mediated through liga-
tion of co-stimulatory and co-inhibitory receptors, which 
are engaged by specific ligands expressed on APCs. The 
key co-stimulatory and co-inhibitory receptor-ligand 
pairs belong to the B7 and tumor necrosis factor (TNF) 
families [228, 229] although accessory molecules belong-
ing to different families might also be important. The dis-
covery that cytotoxic T-lymphocyte-associated protein 
4 (CTLA4)- and programmed cell death protein 1 (PD-
1)-dependent mechanisms provide the basis for the phys-
iologic peripheral immunological tolerance supported 
the rationale that blocking the inhibitory signals medi-
ated by CTLA-4 or PD-1 would promote activation of T 
cells that can recognize tumor antigens and induce anti-
tumor responses. Importantly, the ligands of CTLA-4 
B7-1 (CD80) and B7-2 (CD86) are expressed on antigen 
presenting cells (APC) but not on cancer cells, whereas 
the ligands of PD-1, PD-L1 and PD-L2, are expressed on 
APC and on cancer cells [12, 13]. The properties of these 
inhibitory immune checkpoint pathways leading to can-
cer immune evasion fostered the establishment of novel 
cancer immunotherapies.
Currently, there is only limited knowledge regarding 
the metabolic consequences induced in T cells and/or 
tumor cells by targeting these immune checkpoint path-
ways. Laboratory studies provide evidence that inhibitory 
checkpoint pathways can alter metabolic reprogram-
ming of T cells [15, 230]. T cells receiving PD-1 signals 
are unable to engage in glycolysis, glutaminolysis, or 
amino acid metabolism but display an increased rate 
of FAO [15]. This effect of PD-1 is due to inhibition of 
glucose and glutamine transport as well as inhibition of 
HK2, which catalyzes the first step of glycolysis. These 
studies also determined that PD-1 promotes FAO of 
endogenous lipids by inhibiting the lipid oxidation PI3K 
pathway, resulting in increased expression of the rate-
limiting enzyme of mitochondrial FAO carnitine palmi-
toyltransferase 1A (CPT1A), which plays an important 
role in the utilization of fatty acids as an energy source 
[231]. In addition, PD-1 induces lipolysis, as determined 
by the increase of the major triacylglycerol hydrolase des-
nutrin/adiposite triglyceride lipase (ATGL) and release of 
fatty acids and glycerol. Concomitantly, PD-1 decreases 
lipid biosynthesis, which normally occurs during T cell 
activation, by abrogating the induction of fatty acid syn-
thase (FASN). Consistent with the increased rate of FAO, 
PD-1 induces a significant elevation of the ketone body 
3-hydroxybutyrate, which is produced during FAO. Com-
pared to T cells activated without PD-1 ligation, activated 
T cells receiving PD-1 signals have lower extracellu-
lar acidification rate (ECAR), an indicator of glycolysis, 
and lower oxygen consumption rate (OCR), an indica-
tor of oxidative phosphorylation, but have higher OCR/
ECAR ratio [15]. These findings indicate that in contrast 
to proliferating T cells, which preferentially use glycoly-
sis for energy production, T cells receiving PD-1 signals 
are rather metabolically quiescence and preferentially use 
oxidative phosphorylation over glycolysis as indicated by 
the higher OCR/ECAR ratio. The enhancement of FAO 
also points to a mechanistic explanation for the lon-
gevity of T cells receiving PD-1 signals in patients with 
chronic infections and cancer and for their capacity to 
be reinvigorated by PD-1 blockade. Thus, PD-1 ligation 
alters the metabolic reprogramming induced upon T cell 
activation by inhibiting glycolysis and promoting FAO. 
In contrast, although CTLA-4 inhibits expression of the 
glutamine and glucose transporters, it inhibits glycolysis 
without augmenting CPT1A and FAO, suggesting that 
CTLA-4 maintains immune quiescence by preserving 
the metabolic profile of non-stimulated cells. The role of 
PD-1 signaling in restraining T cell glucose metabolism 
in vivo is also supported by another study in which allo-
geneic PD-L1−/− bone marrow transplant recipients had 
elevated levels of Glut1 and lactate production [232].
In addition to its effects on metabolic reprogramming 
of T cells, the PD-1: PD-L1 pathway may also have impli-
cations on the metabolism of cancer cells. It has been 
observed that subpopulations of established human and 
murine melanoma cell lines as well as subpopulations 
of malignant cells in melanomas from patients’ biopsies 
express PD-1 [233, 234]. Unlike T cells in which PD-1 
ligation causes inhibition of PI3K/Akt and MAPK path-
ways, PD-1 ligation in melanoma cells was found to acti-
vate these pathways and to induce mTOR signaling. In 
this context, ligation of PD-1 with PDL-1 in melanoma 
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cells augments the mTOR-signaling pathway and pro-
motes the expression of glycolytic enzymes, which cor-
relate with tumor growth. Thus, tumor cells may use this 
pathway not only to escape immune response by sup-
pressing activation and expansion of tumor-infiltrating T 
cells but, potentially, to actively support their growth by 
triggering mTOR signaling in trans in neighboring tumor 
cells thereby creating an intra-tumoral growth signal. It 
has also been reported that PD-L1 expressed on tumor 
cells can activate glycolysis and cancer cell growth [16]. 
Although it is unclear how PD-L1, which has a short 
cytoplasmic chain without an evident signaling motif, 
would be ligated under physiologic conditions to trig-
ger tumor-specific activation of glycolytic metabolism, 
together these findings [16, 234] suggest that the PD-1: 
PD-L1 pathway may have significant implications not 
only on T cell anabolic metabolism but also on cancer 
cell metabolism and growth.
Harnessing metabolism therapeutically 
against cancer
So far there has been an extensive characterization of 
the metabolic features and aberrations in cancer. Cancer 
cell growth and survival relies on altered metabolic path-
ways such as aerobic glycolysis, fatty acid synthesis, and 
glutamine metabolism. In addition, emerging evidence 
points to a link between resistance in cancer treatment 
and deregulated cancer metabolism. Targeting cancer 
metabolism has therefore emerged as a promising new 
strategy for the development of anticancer agents either 
used alone or in combination therapies. Such drugs target 
signaling mediators including enzymes and transcription 
factors linked to pathways involved in cancer metabolism 
[235]. To date, only few of these drugs are FDA approved 
due to unwanted side effects, whereas many are in clinical 
testing or at pre-clinical stage of development [236, 237]. 
Examples of such drugs targeting the glycolytic pathway 
include inhibitors of GLUTs, HK, PKM2 or LDHA [235, 
236, 238]. Other drugs target the PPP through inhibition 
of G6P with the goal to inhibit generation of nucleotide 
precursors. A G6P inhibitor, 6-aminonictinamide (6-AN), 
has efficacy against cancer cells in vitro [239, 240]. Other 
inhibitors of the PPP pathway such as resveratrol and 
dehydroepiandrosterone (DHEA) have also shown prom-
ising in vitro anti-cancer effects [235, 241]. Compounds 
targeting lipid metabolism have also been tested as anti-
cancer drugs with the goal to decrease energy generation 
through FAO or to limit precursors for synthesis of fatty 
acid, which are necessary for cancer cell proliferation. For 
example, metformin, the FDA-approved and widely used 
anti-diabetic drug inhibits acetyl-CoA carboxylase (ACC) 
through increased AMPK activation, and there are pre-
clinical and clinical data suggesting its anticancer effects 
[236, 242–244]. In addition, inhibitors of FASN such as 
the FDA-approved drug orlistat are under preclinical 
evaluation for cancer treatment [235, 242]. Furthermore, 
inhibitors of FAO, such as the CPT1 inhibitor ranola-
zine, an FDA-approved compound for the treatment of 
angina, have shown promising anti-cancer effects [235, 
242, 245, 246]. Despite the beneficial effects on anti-
tumor treatment of such metabolism-targeting drugs, 
potential effects on the immune system have not yet been 
examined. However, it should be noted that when used 
in vivo, such metabolism-targeting drugs might mediate 
unwanted side effects on healthy tissues and organs that 
depend on the metabolic pathways targeted. For example, 
preclinical studies with 6-AN showed severe cytotoxicity 
on neuronal and hematopoietic cells [239, 240].
After the clinical success of antibodies against check-
point inhibitors in multiple types of cancer, the role 
of the adaptive immune system in fighting cancer has 
become unequivocal. As a consequence, every effort to 
develop anti-tumor drugs is now accompanied by tests of 
such drugs on immune cells with the goal to confirm that 
no unwanted immunosuppressive function that would 
compromise anti-tumor immunity will be induced. Ide-
ally, anti-tumor drugs or combination therapies should 
prevent tumor growth but simultaneously favor pro-
longed anti-tumor T cell function so that functional 
anti-tumor T cells can develop and possibly synergize 
with the tumor-specific cytotoxic functions of the thera-
peutic compound. A major goal of novel immunomodu-
latory approaches is the generation of tumor-specific 
Tm in parallel to the generation of Teff cells. This will 
allow for sustained immune-mediated anti-tumor func-
tion instead of a transient anti-tumor effect. For exam-
ple, metformin, an anti-diabetic drug that, as mentioned 
above, has also shown direct clinical efficacy in cancer 
[243, 244], is an AMPK activator. As a consequence, 
metformin inhibits mTOR and glycolysis, thereby inhib-
iting tumor growth. Importantly, metformin also inhib-
its glycolysis by mediating direct inhibitory effects on 
key components of the glycolytic pathway including the 
rate-limiting enzyme of glycolysis HK2 [247, 248]. How-
ever, via these mechanisms metformin also promotes 
development of Treg [18] and long-lived Tm cells [154]. 
In addition, mTOR inhibiting compounds such as rapa-
mycin can also have metabolism-targeting effects on T 
cells, and although rapamycin is traditionally being used 
as immunosuppressant, it can promote memory CD8+ 
T cell formation when administered after an acute viral 
or bacterial infection [81, 154, 155]. Thus the use of 
metabolism-targeting drugs together with checkpoint 
inhibitors might alter the activation and differentiation 
program of tumor-specific T cells and prevent the gen-
eration of exhausted T cells.
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Conclusions and future directions
T cells and cancer cells inexorably share metabolic pro-
grams and preferences, and thus there is high competi-
tion for nutrients between cancer and T cells within 
the tumor microenvironment. Nutrient deprivation, 
increased metabolic waste, and the ability of tumors to 
express inhibitory ligands impair the metabolic fitness 
and capacity of T cells to uptake and utilize nutrients. 
Additionally, metabolism determinants of the tumor 
microenvironment drive T cells to exhaustion and Treg 
differentiation programs rather than Teff and Tm phe-
notypes leading to impaired antitumor responses. The 
changes and adaptations in the tumor microenviron-
ment most likely are not limited to solid tumors because 
leukemia and lymphoma cells have similar metabolic 
characteristics with solid tumors and often express 
immunomodulatory ligands [249–252]. In addition, 
lymphomas may also contain infiltrating T cells with an 
exhausted phenotype similar to that identified in chronic 
viral infections or solid tumors [249]. Thus, drugs that 
directly target key metabolic enzymes or their upstream 
regulators will likely interfere with metabolism of both 
cancer and T cells in which core cell signaling and meta-
bolic pathways converge. Understanding the similarities 
and differences of metabolic vulnerabilities of T cells and 
cancer may lead to the development of single-target or 
combination-based therapies to modify metabolism of 
the tumor niche thereby targeting both cancer cells and 
immune cells. Identification of such specific changes in 
oncometabolites and immunometabolites may define 
not only novel therapeutic targets but also biomark-
ers for assessment of therapeutic responses to tumor-
immunotherapy combined with metabolism-targeting 
drugs. The ultimate goal is to design metabolism-based 
treatment strategies to attack and eradicate cancer while 
promoting effective and sustainable anti-tumor T cell 
responses.
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